View profile

FarmaKology-Lonza and Touchlight collaborate on end-to-end mRNA offering

Revue
 
 

FarmaKology

September 6 · Issue #107 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+16K Subscribers )!

FarmaKology-Lonza and Touchlight collaborate on end-to-end mRNA offering
FarmaKology-Lonza and Touchlight collaborate on end-to-end mRNA offering
Novo Banking
Novo Banking
Today's Company
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc.
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types.
News
MannKind Corporation , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101) and is planning discussions with the U.S. Food and Drug Administration (FDA) regarding results and the ongoing clinical program.
 Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced a collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution. Through this collaboration, Lonza will have the ability to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA (mRNA) therapeutics and vaccines, while Touchlight can widen the channels through which customers can gain access to its novel doggybone DNA (dbDNA) technology. 
Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today a summary of its Type C Clinical meeting minutes with the U.S. Food and Drug Administration (FDA) relating to its lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with recurrent glioblastoma (GBM).
Digital therapeutics company HealthBeacon has announced a new commercial partnership with the American Pharmacists Association Foundation. The Dublin headquartered firm develops products for managing injectable medications for people in the home.
Research & Study
Podcast
September 2nd, 2022 - The Top Line - Omny.fm
Job Opportunities
Upcoming Webinar & Event
Video
Interview with Florence Healthcare CEO Ryan Jones
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue